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Changing concepts: Liver replacement for 
hereditary tyrosinemia and hepatoma 
IN RECENT YEARS there has been increased use of hepatic 
transplantation for the treatment of liver-based inborn 
errors of metabolism. i,2 In 1976, a 9-year-old girl with 
chronic hereditary tyrosinemia who had developed a IS-cm 
hepatoma in her cirrhotic liver underwent liver replace-
ment with immunosuppression therapy with azathioprine, 
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prednisone, and antilymphocyte globulin. The abnormal 
metabolic profile of tyrosinemia was promptly and com-
pletely corrected, but a pulmonary metastasis from the 
hepatoma was discovered shortly afterward. The new liver 
was rejected in 3 months, and the patient died during a 
second attempt at transplantation. 3 
We have had subsequent experience with four additional 
patients with the same diagnoses, in whom immunosup-
pression therapy after liver replacement was with cyclospo-
rine and prednisone. These four recipients are well and 
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Table. Clinical features 
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Liver function 
Age 
Patient (yr) 
21 
2 
3 
4 3 
"Normal <20. 
Date of 
transplantation 
3/20/83 
11/14/81 
5/13/83 
1/25/84 
5/28/84 
Preoperative 
a-fetoprotein* 
(ng/ml) 
2,740t 
>25,000 
4,600 
13,560 
tBefore right hepatic lobectomy, 1/1983 (see text). 
Total 
serum 
bilirubin 
(mg/dl) 
2.9 
1.8 
1.8 
3.7 
metabolically normal 3 months to almost 3 years after 
transplantation and have no evidence of recurrent tumor. 
These observations suggest the desirability of liver trans-
plantation earlier in the course of this disease. The point 
has been supported by experience with a fifth candidate 
whose proposed transplantation was interdicted by metas-
tases to the diaphragm, which were discovered at the 
time of operation. This 4-year-old girl died 1 Y2 months 
later. 
The four recipients, who received treatment in the 
cyclosporine era, were 2Y2 to 21 years of age. Each had 
cirrhosis and multiple abnormalities of liver function, 
including prolonged prothrombin time and low-grade 
hyperbilirubinemia (Table). The diagnosis had been made 
early in life by the demonstration at established metabolic 
centers of hypertyrosinemia, tyrosinuria, and marked 
excretion of tyrosine metabolites in the urine, which were 
managed with a diet low in tyrosine and phenylalanine. 
In three of the patients, elevations of a-fetoprotein 
(Table) originally aroused suspicion of hepatoma develop-
ment. However, a definite mass was detectable with 
computed tomography and other radiographic techniques 
only in the oldest (patient 1). This patient underwent a 
right hepatic lobectomy at another hospital, at which time 
the main portal vein was accidentally tied off; the hepato-
ma was thought to be cleanly removed. After the right-
sided lobectomy, she developed very severe liver failure and 
was bedridden until the time of transplantation 2 months 
later. There was no residual tumor in the hepatic remnant. 
In patient 2 the diagnosis of hepatoma had been suspected 
after a routine ultrasound examination, and was confirmed 
by open liver biopsy. 
Patients 2, 3, and 4 had multiple small hepatomas in all 
Prothrombin 
time 
(sec) 
Patient I Control 
17.0 11.6 
15.0 12.5 
17.0 12.0 
15.0 11.5 
Hepatoma(s) 
in specimen 
from 
transplantation 
None; tumor 
removed by 
previous right 
lobectomy 
Multiple 
Multiple 
Multiple 
Referral source 
UniversIty of Cmcmattl 
William Balistreri, M.D. 
Cornell University 
Maria New, M.D. 
University of Chicago 
Lawrence Gartner, M.D. 
Children's Hospital of 
Dayton 
Stephan Newman, M.D. 
parts of the excised livers. However, the surgical margins 
were free of tumor. 
Although the livers were cirrhotic, they were relatively 
soft. The transplantation procedures were by well-stan-
dardized techniques, 1,4 except in the child who had under-
gone right hepatic lobectomy, whose portal vein was 
thrombosed from the site of surgical ligature back to the 
confluence of the splenic and superior mesenteric veins. In 
this recipient a cloaca was fashioned at the superi9r 
mesenteric-splenic venous junction, to which a free inferi-
or vena caval graft from the liver donor was anastomosed. 
The donor portal vein was anastomosed, in turn, to the 
proximal end of this graft. 5 
Cyclosporine and prednisone were given intravenously 
or orally from the time of operation, with rapid weaning 
from prednisone to maintenance doses, presently 2.5 to 7.5 
mg/day. Despite therapy, one of the recipients (patient 2) 
slowly rejected the graft, and retransplantation was carried 
out without incident 18 months after the primary proce-
dure. She is well 15112 months after retransplantation. The 
other three recipients also are well after 3, 7, and 17 
months, respectively. 
The a-fetoprotein levels, which ranged from 4600 to 
25,000 ng/ml before liver replacement (or before hepatic 
resection in patient 1) fell to within the normal range 
within a few days or weeks, and have remained normal. 
There has been no evidence of recurrent hepatoma in any 
patient, and all four now have normal liver function. The 
metabolic abnormalities characteristic of tyrosinemia were 
normalized immediately after transplantation, even 
though the patients were given a regular diet. 
Detailed studies of amino acid metabolism have been or 
are being carried out in the referring centers (Table) and 
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will be described separately. It is now thought that 
hereditary tyrosinemia is caused by fumarylacetoacetate 
hydrolase deficiency.6.s In other liver-based inborn errors 
of metabolism with or without a specific and identifiable 
enzyme defect, the metabolic phenotype of the graft has 
remained permanently that of the donor. I, 2 Thus the 
metabolic amelioration in our patients with tyrosinemia 
should be for the lifetime of the grafts. 
The use ofliver transplantation for "metabolic engineer-
ing" has been a tantalizing prospect for a number of years, 
but the poor results with liver replacement discouraged the 
wide application of this approach until recently. With the 
advent of immunosuppression therapy with cyclosporine 
and steroids, the prognosis after liver replacement has 
improved so dramatically, particularly in pediatric recipi-
ents, that reluctance to go forward with this aggressive 
therapy has diminished.' Furthermore, the increasingly 
recognized risk of hepatoma formation9 is an additional 
and potent reason to consider liver transplantation at an 
earlier time and under semielective conditions, 
In the early days of liver transplantation, efforts to treat 
hepatomas that could not be excised by conventional 
techniques resulted in an incidence of tumor recurrence so 
high that the potential value of the operation was viti-
ated.,,4 With better patient selection in more recent times, 
this incidence of recurrence has been reduced, 1 and in 
patients with hepatomas incidental to tyrosinemia, a,-
antitrypsin deficiency, sea-blue histiocyte syndrome, or 
biliary atresia, the incidence of recurrence has been zero. 
Thus, the threat of late metastases in the four surviving 
patients with tyrosinemia is not as great as might have 
been predicted from the older literature. 
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